The Act4Biosimilars Action Plan aims to highlight key challenges preventing patient access to biosimilars and outline steps to help overcome them.
Antiobesity medications are considered to be 'vanity drugs' by many private insurers, and the refusal to cover obesity treatment is counterproductive because of obesity's many health consequences.
The accelerated approval of delandistrogene moxeparvovec-rokl is “based on expression of Elevidys micro-dystrophin observed in patients treated with ELEVIDYS,” according to Sarepta Therapeutics.
A recent review evaluated possible approaches for new vaccines targeting respiratory viruses.
A study presented at Digestive Disease Week 2023 compared the effectiveness of different approaches to prevent complications in individuals with the common disease.